Selank

Moderate Evidence

What Is Selank?

Selank is a synthetic heptapeptide consisting of seven amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a synthetic analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that is produced by enzymatic cleavage of the Fc domain of immunoglobulin G and is known for its immunomodulatory properties [1].

The selank molecule extends the tuftsin sequence with a Pro-Gly-Pro tail, which researchers designed to enhance metabolic stability and prolong the peptide’s biological half-life. This structural modification allows selank to resist rapid enzymatic degradation, a common limitation of short peptides [2].

Selank has been approved in Russia as an anxiolytic medication and is marketed there for the treatment of generalised anxiety disorder and as a nootropic agent. It has been the subject of clinical trials conducted primarily in Russian research institutions. Outside of Russia, selank is not approved for human therapeutic use by the FDA, MHRA, TGA, or other major regulatory bodies. Individuals considering selank should consult a qualified healthcare provider and understand the regulatory status in their jurisdiction.

Mechanism of Action

Research suggests that selank exerts its effects through multiple neurochemical and immunological pathways:

GABAergic modulation. Studies indicate that selank may influence gamma-aminobutyric acid (GABA) signalling in the central nervous system. Research by Seredenin et al. suggests that selank may enhance the inhibitory effects of GABA, potentially contributing to its reported anxiolytic properties without producing the sedation or dependence associated with benzodiazepines [3].

Monoamine modulation. Animal studies indicate that selank may influence serotonin metabolism in the brain. Research suggests the peptide may stabilise enkephalin levels and modulate the balance of serotonin and norepinephrine in brain regions associated with anxiety and mood regulation [4].

BDNF expression. Preclinical research suggests that selank may increase the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus, a protein critical for neuronal survival, synaptic plasticity, and memory formation [5]. This mechanism may underlie some of the reported cognitive-enhancing properties.

Immunomodulatory effects. As an analogue of tuftsin, selank retains immunomodulatory properties. Research indicates it may influence the expression of interleukin-6 (IL-6) and affect the balance of T-helper cell subtypes, suggesting a modulatory rather than purely stimulatory or suppressive effect on immune function [1][6].

Research and Evidence

Anxiolytic Effects

The most extensively studied application of selank is anxiety reduction. Clinical trials conducted in Russia have evaluated selank’s efficacy in patients with generalised anxiety disorder (GAD). A study by Zozulya et al. (2008) reported that intranasal selank administration produced significant reductions in anxiety scores compared to baseline, with efficacy comparable to the benzodiazepine medazepam but without sedative effects or withdrawal symptoms [3].

Additional Russian clinical studies have examined selank in patients with anxiety-asthenic disorders, reporting improvements in anxiety measures and general wellbeing [7]. It is important to note that many of these clinical trials were conducted under Russian regulatory standards, and the study designs may not fully align with the randomised, double-blind, placebo-controlled standards typical of FDA or EMA drug approval processes.

Cognitive Enhancement

Animal studies suggest that selank may enhance learning and memory processes. Research in rodent models has demonstrated improved performance in maze-navigation and passive avoidance tasks following selank administration [5]. These effects are hypothesised to be mediated through BDNF upregulation and modulation of monoamine systems in the hippocampus and prefrontal cortex.

Limited human data from Russian clinical studies suggests that selank may improve attention, memory, and cognitive processing speed in patients with anxiety-related cognitive impairment [8]. However, well-controlled studies in healthy populations are limited.

Immune Function

Research has explored selank’s immunomodulatory properties, which derive from its structural relationship to tuftsin. Animal and in-vitro studies indicate that selank may enhance natural killer cell activity, modulate cytokine expression, and influence innate immune responses [6]. Some research suggests potential applications in immune support during periods of stress, though clinical evidence for this application remains preliminary.

Dosage and Administration

Important: The following information reflects dosages reported in research literature and the approved Russian formulation. Selank is not approved outside of Russia, and no international dosing guidelines exist. Always consult a qualified healthcare provider before considering any peptide protocol.

Common Research and Community-Reported Protocols

• Intranasal spray: 200-400 mcg per day, divided into 2-3 administrations. The approved Russian formulation uses a 0.15% intranasal solution. Nasal administration provides relatively rapid absorption and is the most commonly referenced route.
• Subcutaneous injection: 250-500 mcg per day. Some community protocols reference subcutaneous injection, though the intranasal route is more widely studied.

Administration Notes

Selank is most commonly administered as an intranasal spray, which offers ease of use and avoids the need for reconstitution and injection. When supplied as a lyophilised powder for injection, standard reconstitution with bacteriostatic water applies. Use the reconstitution calculator for precise mixing guidance.

Cycling

Community protocols often reference cycles of 2-4 weeks, with some Russian clinical literature using treatment periods of 14 days. Extended use beyond these periods has not been comprehensively studied.

Side Effects and Safety

Selank has demonstrated a favourable safety profile in Russian clinical studies, though comprehensive international safety data is limited.

Observed in clinical studies: Russian clinical trials have reported minimal adverse effects at therapeutic doses. Selank did not produce the sedation, cognitive impairment, or dependence associated with benzodiazepine anxiolytics [3][7].

Community-reported side effects (anecdotal, not clinically validated):

• Mild nasal irritation with intranasal use
• Transient fatigue in the initial days
• Mild headache
• Occasional dizziness

Potential concerns and unknowns:

• Long-term safety data beyond the durations studied in Russian clinical trials is limited
• Drug interactions have not been comprehensively characterised
• Effects on pregnancy and lactation have not been studied; use should be avoided in these populations
• Immunomodulatory effects suggest caution in individuals with autoimmune conditions
• Quality and purity of research-grade selank available outside of Russia may vary significantly

Frequently Asked Questions

Is selank the same as semax?

Selank and semax are both synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are approved in Russia. However, they have different parent molecules and primary mechanisms. Selank is derived from tuftsin and primarily targets anxiety and immune modulation, while semax is derived from an ACTH fragment and primarily targets cognitive enhancement and neuroprotection. Some community protocols use both peptides concurrently.

Does selank cause dependence?

Russian clinical studies have not reported physical dependence or withdrawal symptoms with selank use, which distinguishes it from benzodiazepine anxiolytics [3]. However, long-term dependence studies with the rigour expected by international regulatory bodies have not been conducted.

How quickly does selank work?

Russian clinical data suggests that anxiolytic effects may begin within the first few days of administration, with more substantial effects observed over a 14-day treatment course [7]. The onset may be faster with intranasal administration due to relatively rapid absorption through the nasal mucosa.

Can selank be combined with other nootropics?

There is limited clinical research on selank combinations. Some community protocols combine selank with semax, though this combination has not been formally evaluated in controlled trials. Any combination protocol should be discussed with a qualified healthcare provider.

Is selank approved anywhere for medical use?

Selank is approved in Russia as an anxiolytic and nootropic medication. It is not approved by the FDA, MHRA, TGA, EMA, or other major international regulatory agencies. The clinical evidence base, while including human studies, has been generated primarily within the Russian research and regulatory framework.

References

References

1. Uchakina ON, et al. Immunomodulatory activity of the synthetic peptide selank. Bulletin of Experimental Biology and Medicine. 2008;146(6):726-728.
2. Kozlovskii II, Danchev ND. Optimising pharmacological properties of tuftsin-derived peptides: the development of selank. Neuroscience and Behavioral Physiology. 2003;33(2):181-184.
3. Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalised anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii. 2008;108(4):38-48.
4. Seredenin SB, et al. Effects of selank on serotonin metabolism in the brain of rats with various anxiety levels. Bulletin of Experimental Biology and Medicine. 2006;142(3):335-338.
5. Inozemtseva LS, et al. Effect of selank on BDNF expression in the hippocampus and cognitive function in rats. Doklady Biological Sciences. 2008;421(1):241-243.
6. Kozlov VA, et al. Immunoregulatory properties of selank: effect on T-helper cell subpopulations. Immunologiya. 2007;28(4):214-218.
7. Medvedev VE, et al. Clinical efficacy and tolerability of selank in anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii. 2014;114(7):87-93.
8. Seredenin SB, Gudasheva TA. Selank and semax: peptide anxiolytics with nootropic activity. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2012;(7):47-52.
9. Klimova RR, et al. Antiviral properties of selank peptide. Voprosy Virusologii. 2010;55(5):23-27.
10. Meshavkin VK, et al. Neuroprotective effects of selank in models of oxidative stress. Eksperimental'naya i Klinicheskaya Farmakologiya. 2011;74(3):12-16.

Continue Reading

Readers also explore

All peptides →

Cognitive

Semax

Semax (ACTH 4-10 Analogue)

cognitive enhancement · neuroprotection · focus

Open profile